Figure 8.
Mice treated with a CMA activating drug have enhanced lysosomal enrichment of nucleocytosolic acetyl-coA and fatty acid synthesis enzymes in response to leupeptin treatment. (A) Western blots for indicated proteins in liver lysosomes isolated from mice treated with buparlisib or solvent control that were also treated with leupeptin or solvent control 2 h before being sacrificed. LAMP2A is a loading control. CTSD is a control for successful administration of leupeptin. (B) Quantification of Western blots shown in (A). Black bars indicate means and SEM. PINT, shown below each graph, is the interaction term p-value from a 2-way ANOVA. p values shown on graphs in are derived from unpaired t-tests.